NCT00002371已完成3 期
A Randomized Double-Blind Study of Safety, Virologic and Immunological Effects of Stavudine Plus Lamivudine (3TC) Versus Zidovudine Plus Lamivudine in HIV-Infected Subjects Following At Least Six Months of Zidovudine Therapy
Bristol-Myers Squibb14 个研究点 分布在 3 个国家目标入组 80 人开始时间: 1996年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 14
研究概览
简要总结
To compare the magnitude and durability of the reduction in plasma HIV RNA in the two treatment groups over the first 12 weeks of treatment. To determine the safety of each of the two treatment groups.
详细描述
Patients will be randomized to either Stavudine (d4T) + Lamivudine (3TC) + Zidovudine placebo or Zidovudine (ZDV) + Lamivudine + Stavudine placebo. Patients whose plasma HIV RNA levels remain >= 500 copies/ml after 8 weeks of blinded double combination therapy will have indinavir added to their treatment regimen at the week 12 visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •At least six months of prior cumulative ZDV therapy.
- •Qualifying plasma HIV RNA count of >= 4 log10 copies/ml obtained within 2 weeks of randomization.
排除标准
- •Co-existing Condition:
- •Patients with any of the following symptoms or conditions are excluded:
- •Presence of newly diagnosed AIDS defining opportunistic infection requiring acute therapy at time of enrollment.
- •Intractable diarrhea (>= 6 loose stools/day for >= 7 consecutive days).
- •Signs and symptoms of bilateral peripheral neuropathy >= grade 2 at the time of screening.
- •Inability to tolerate oral medication.
- •Any other clinical conditions that in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing requirements.
- •Concurrent Medication:
- •Therapy with agents with systemic myelosuppressive, neurotoxic pancreatotoxic, hepatotoxic or cytotoxic potential.
- •Therapy with rifampin, rifabutin, terfenadine, astemizole, cisapride, triazolam, midazolam and ketoconazole at any time while on indinavir therapy.
- •Patients with any of the following prior conditions or symptoms are excluded:
- •History of acute or chronic pancreatitis.
- •Prior history of bilateral peripheral neuropathy.
- •Intractable diarrhea (>= 6 loose stools/day for >= 7 consecutive days) within 30 days prior to study entry.
- •Prior Medication:
- •Any prior antiretroviral therapy except for ddI, ddC, 3TC or ZDV (for ZDV, as specified in inclusion criteria).
- •Previous therapy with agents with significant systemic myelosuppressive, neurotoxic pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start.
- •Therapy with rifampin, rifabutin, terfenadine, astemizole, cisapride, triazolam, midazolam and ketoconazole within 2 weeks prior to starting indinavir.
- •Any other prior therapy that, in the opinion of the investigator, would make the patient unsuitable for study or unable to comply with the dosing regimen.
- •Risk Behavior:
- •Active alcohol abuse, sufficient in the investigator's opinion, to prevent compliance with study therapy or to increase the risk of developing pancreatitis.
- •At least 6 months of prior cumulative ZDV therapy.
研究者
研究点 (14)
Loading locations...
相似试验
已完成
2 期
A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected PatientsHIV InfectionsNCT00001084National Institute of Allergy and Infectious Diseases (NIAID)500
已完成
4 期
Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIVHIV InfectionsNCT00256828Clinical Trial Agency of HIV Study Group360
已完成
不适用
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-NaiveHIV InfectionsNCT00002215Triangle Pharmaceuticals
已完成
不适用
Effects of Anti-HIV Therapy on Nervous System FunctionHIV InfectionsNCT00432003National Institute of Allergy and Infectious Diseases (NIAID)297
已完成
2 期
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their BloodHIV InfectionsNCT00000916National Institute of Allergy and Infectious Diseases (NIAID)399